Cargando…
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843946/ https://www.ncbi.nlm.nih.gov/pubmed/36647169 http://dx.doi.org/10.1186/s40164-023-00372-8 |
_version_ | 1784870512541827072 |
---|---|
author | Ma, Weijie Xue, Ruobing Zhu, Zheng Farrukh, Hizra Song, Wenru Li, Tianhong Zheng, Lei Pan, Chong-xian |
author_facet | Ma, Weijie Xue, Ruobing Zhu, Zheng Farrukh, Hizra Song, Wenru Li, Tianhong Zheng, Lei Pan, Chong-xian |
author_sort | Ma, Weijie |
collection | PubMed |
description | Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent with chemotherapy at a response rate of around 20–30% with a few exceptions. With significant progress over the decade, advances in immunotherapy have led to numerous clinical trials investigating ICIs as neoadjuvant and/or adjuvant therapies for resectable solid tumors. The promising results of these trials have led to the United States Food and Drug Administration (FDA) approvals of ICIs as neoadjuvant or adjuvant therapies for non-small cell lung cancer, melanoma, triple-negative breast cancer, and bladder cancer, and the list continues to grow. This therapy represents a paradigm shift in cancer treatment, as many early-stage cancer patients could be cured with the introduction of immunotherapy in the early stages of cancer. Therefore, this topic became one of the main themes at the 2021 China Cancer Immunotherapy Workshop co-organized by the Chinese American Hematologist and Oncologist Network, the China National Medical Products Administration and the Tsinghua University School of Medicine. This review article summarizes the current landscape of ICI-based immunotherapy, emphasizing the new clinical developments of ICIs as curative neoadjuvant and adjuvant therapies for early-stage disease. |
format | Online Article Text |
id | pubmed-9843946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98439462023-01-18 Increasing cure rates of solid tumors by immune checkpoint inhibitors Ma, Weijie Xue, Ruobing Zhu, Zheng Farrukh, Hizra Song, Wenru Li, Tianhong Zheng, Lei Pan, Chong-xian Exp Hematol Oncol Review Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent with chemotherapy at a response rate of around 20–30% with a few exceptions. With significant progress over the decade, advances in immunotherapy have led to numerous clinical trials investigating ICIs as neoadjuvant and/or adjuvant therapies for resectable solid tumors. The promising results of these trials have led to the United States Food and Drug Administration (FDA) approvals of ICIs as neoadjuvant or adjuvant therapies for non-small cell lung cancer, melanoma, triple-negative breast cancer, and bladder cancer, and the list continues to grow. This therapy represents a paradigm shift in cancer treatment, as many early-stage cancer patients could be cured with the introduction of immunotherapy in the early stages of cancer. Therefore, this topic became one of the main themes at the 2021 China Cancer Immunotherapy Workshop co-organized by the Chinese American Hematologist and Oncologist Network, the China National Medical Products Administration and the Tsinghua University School of Medicine. This review article summarizes the current landscape of ICI-based immunotherapy, emphasizing the new clinical developments of ICIs as curative neoadjuvant and adjuvant therapies for early-stage disease. BioMed Central 2023-01-16 /pmc/articles/PMC9843946/ /pubmed/36647169 http://dx.doi.org/10.1186/s40164-023-00372-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Ma, Weijie Xue, Ruobing Zhu, Zheng Farrukh, Hizra Song, Wenru Li, Tianhong Zheng, Lei Pan, Chong-xian Increasing cure rates of solid tumors by immune checkpoint inhibitors |
title | Increasing cure rates of solid tumors by immune checkpoint inhibitors |
title_full | Increasing cure rates of solid tumors by immune checkpoint inhibitors |
title_fullStr | Increasing cure rates of solid tumors by immune checkpoint inhibitors |
title_full_unstemmed | Increasing cure rates of solid tumors by immune checkpoint inhibitors |
title_short | Increasing cure rates of solid tumors by immune checkpoint inhibitors |
title_sort | increasing cure rates of solid tumors by immune checkpoint inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843946/ https://www.ncbi.nlm.nih.gov/pubmed/36647169 http://dx.doi.org/10.1186/s40164-023-00372-8 |
work_keys_str_mv | AT maweijie increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT xueruobing increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT zhuzheng increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT farrukhhizra increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT songwenru increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT litianhong increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT zhenglei increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors AT panchongxian increasingcureratesofsolidtumorsbyimmunecheckpointinhibitors |